1 – 12 of 12
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis
(
- Contribution to journal › Article
-
Mark
Impact on follow-up strategies in patients with primary sclerosing cholangitis
(
- Contribution to journal › Article
- 2022
-
Mark
Patterns of Respiratory Support by Gestational Age in Very Preterm Infants
2022) In Neonatology(
- Contribution to journal › Article
-
Mark
Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes : A nationwide study
(
- Contribution to journal › Article
-
Mark
Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates
(
- Contribution to journal › Article
-
Mark
Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases : A Nationwide Cohort Study
2022) In Clinical Gastroenterology and Hepatology(
- Contribution to journal › Article
- 2021
-
Mark
Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register–a validation study
(
- Contribution to journal › Article
-
Mark
Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine
(
- Contribution to journal › Article
-
Mark
Association Between Collagenous and Lymphocytic Colitis and Risk of Severe Coronavirus Disease 2019
(
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis : results from a nationwide study in Sweden
(
- Contribution to journal › Article
- 2018
-
Mark
Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis A nationwide population-based cohort study
(
- Contribution to journal › Article
-
Mark
Patient-Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics-Treated Patients With Rheumatoid Arthritis
(
- Contribution to journal › Article